A few months after Swedish biotech Cellectricon announced that it had a new distributor in the UK for DynaFlow, its flagship ion-channel screening technology, and that it was opening a US subsidiary, the company's expansion efforts are beginning to pay dividends.

A little over a week ago, Cellectricon announced that AstraZeneca, one of its early beta-test partners in Sweden, has installed DynaFlow platforms at multiple sites, including UK- and US-based laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.